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A poly (A)-binding protein from Leishmania infantum (LiPABP) has been recently cloned
and characterized in our laboratory. Although this protein shows a very high homology with
PABPs from other eukaryotic organisms including mammals and other parasites, exist
divergences along the sequence that convert them in potential diagnostic markers and/or
therapeutics targets. Aptamers are oligonucleotide ligands that are selected in vitro by their
affinity and specificity for the target as a consequence of the particular tertiary structure that
they are able to acquire depending on their sequence. Development of high-affinity mole-
cules with the ability to recognize specifically Leishmania proteins is essential for the prog-
ress of this kind of study.
Results
We have selected a ssDNA aptamer population against a recombinant 6xHIS–LiPABP
protein (rLiPABP) that is able to recognize the target with a low Kd. Cloning, sequencing
and in silico analysis of the aptamers obtained from the population yielded three aptamers
(ApPABP#3, ApPABP#7 and ApPABP#11) that significantly bound to PABP with higher
affinity than the naïve population. These aptamers were analyzed by ELONA and slot blot
to establish affinity and specificity for rLiPABP. Results demonstrated that the three apta-
mers have high affinity and specificity for the target and that they are able to detect an
endogenous LiPABP (eLiPABP) protein amount corresponding to 2500 L. infantum pro-
mastigotes in a significant manner. The functional analysis of the aptamers also revealed
that ApPABP#11 disrupts the binding of both Myc-LiPABP and eLiPABP to poly (A) in vitro.
On the other hand, these aptamers are able to bind and purify LiPABP from complex mixes.
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Conclusion
Results presented here demonstrate that aptamers represent new reagents for characteri-
zation of LiPABP and that they can affect LiPABP activity. At this respect, the use of these
aptamers as therapeutic tool affecting the physiological role of PABP has to be analyzed.
Introduction
Leishmaniasis is caused by Leishmania spp. and is transmitted by sand flies. The disease, also
known as kala-azar (black fever) or Assam fever, has a wide distribution that extends from the
Mediterranean to Middle Asia, to southern Russia and China [1, 2]. Diagnosis of leishmaniasis
is routinely performed by finding the parasite in smears from skin lesions or in bone marrow,
spleen, liver, or blood smears using microscopic examination. However, serological, immuno-
logical and PCR-based methods are being developed [3].
Leishmania is a parasitic protozoan of the trypanosomatids family that possesses a digenetic
life cycle with two discrete morphological phases: the promastigote, which develops extracelul-
larly within the gut of the insect vector, and the amastigote that is specialized to survive within
the macrophage’s phagolysosome of the vertebrate host. Thus, it is assumed that trypanosoma-
tids parasites need a regulated expression of stage-specific genes to survive extreme environ-
mental changes in which poly (A)-binding protein (PABP) regulation could play some role.
Different PABPs have been described in T. cruzi (TcPABP1) [4], T. brucei (TbPABP) [5], L.
major PABP (LmPABP1, LmPABP2 y LmPABP3) [6, 7] or L. amazonensis (LaPABP) [8]. Very
recently, we have described the first PABP homologue from L. infantum, called LiPABP, which
conserves the main domains present in other PABPs and maintains poly(A) binding properties
[9].
The PABP of eukaryotes binds the 3´ end poly (A) tail of the mRNAs and participates in dif-
ferent cellular processes such as translational initiation and termination and in mRNA turn-
over [10–12]. When bound to the poly (A) tail, PABP circularizes mRNAmolecules via its
interaction with translational initiation factors at the cap, enhancing translational initiation
and stabilizing mRNA [10–12]. In addition, interaction with the release factor eRF3 and disso-
ciation of PABP from the poly (A) tail is necessary for progressive deadenylation and conse-
quent decay for many transcripts [13–16]. Furthermore, this protein seems to be involved in
mRNA transport from the nucleus to the cytoplasm [12, 17].
In our laboratory, we are very interested to isolate and characterize aptamers against Leish-
mania proteins in an attempt to develop diagnostic and/or therapeutic tools against leishmani-
asis. At this respect aptamers targeting L. infantum KMP-11 [18, 19], LiH2A [20, 21] and LiH3
[22] have been selected and characterized in our laboratory.
Aptamers are structured polynucleotide sequences isolated from randomized oligonucleo-
tide libraries by systematic evolution of ligands by exponential enrichment (SELEX) technol-
ogy, that selectively bind target molecules with high affinity and specificity [23–25]. Aptamers
are able to form stable and specific complexes with the targets that have dissociation constants
in the nanomolar range due to the highly defined tertiary structures that are able to adopt
depending on their sequence, and can clearly distinguish between even closely related protein
targets [26, 27]. Aptamers have several advantages over antibodies because of the nature of
nucleic acids such as increased stability, easy regeneration and simple modifications with dif-
ferent reporters during their synthesis. In addition, they are significantly smaller, can be iso-
lated rapidly in vitro and do not elicit a significant immune response [28, 29].
Aptamers Targeting L. infantum PABP
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Aptamers are also selected against defined protein target in order to use them as molecular
tools to study the interaction with other molecular partners or to identify their sites of action.
Indeed, aptamers have been generated against transcription factors and shown to interfere
with a range of molecular interactions both in vitro and in vivo [30, 31]. Moreover, further
functional analysis of LiPABP requires molecules that specifically bind the protein target in
order to affect PABP-poly (A) interaction and aptamers compete to antibodies in this purpose.
In addition, molecules recognizing LiPABP might be very important as detection, diagnostic or
therapeutic tools.
In this paper, we have used SELEX to generate a DNA aptamer population that binds
LiPABP with high affinity. In addition, we detail the isolation and characterization of three
aptamers that are able to recognize specifically the protein with affinity in the low nanomolar
range. These aptamers detect LiPABP from 2500 L. infantum promastigotes in a significant
manner and, in consequence, they could be used in the development of diagnostics systems for
leishmaniasis. Furthermore, analysis of selected aptamers reveals that one of them,
ApPABP#11, disrupts the binding of LiPABP to poly (A). This ability of this aptamer may be
used in regulating the function of LiPABP in vivo. In addition, we demonstrate that the three
aptamers are able to bind and purify LiPABP from lysates of cells overexpressing the protein.
This capacity would be useful for further characterization of the LiPABP activity.
Materials and Methods
Materials
Products were obtained from Sigma-Aldrich (Spain) except those indicated in the text. RND40
starting population, individuals DNA aptamers, and their derivatives were purchased from
IBA GmbH (Göttingen, Germany).
Cell culture and extract preparation
Leishmania infantum (MCAN/ES/96/BCN150) promastigotes were grown at 26°C in RPMI
1640 medium (PAA Laboratories), supplemented with 10% (v/v) foetal calf serum (PAA Labo-
ratories), 10 U/mL penicillin and 100 μg/mL streptomycin (Gibco). Cultures containing L.
infantum promastigotes were pelleted and lysed in ice-cold RIPA buffer (50 mM Tris-HCl pH
7.6, 150 mMNaCl, 1 mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) and centri-
fugated at 17000 x g for 20 min, to obtain total lysates. Protein determination was performed
by the method of Bradford [32]. The supernatant volume was accurate measured to calculate
that corresponding to 103 L. infantum promastigotes.
Transient transfections with pcDNA3-Myc-LiPABP or pcDNA3-Flag-LiPABP were essen-
tially performed as described previously [33]. After 24 h of transfection, the medium was
removed and the cells washed twice with ice-cold buffer A (20 mM Tris-HCl pH 7.6, 1 mM
DTT, 1 mM EDTA, 1 mM PMSF, 1 mM benzamidine, 2 mM sodium molybdate, 2 mM
sodium β-glycerophosphate, 0.2 mM sodium orthovanadate, 120 mM KCl, 10 μg/mL anti-
paine, 1 μg/mL leupeptin, 1 μg/mL pepstatin) and lysed in the same buffer containing 1% Tri-
ton X-100 (50 μL/106 cells). Cell lysates were centrifuged at 12000 x g for 15 min and the
supernatants were kept at -80°C until used. Protein determination was performed as above.
Expression and purification of recombinant L. infantum proteins
L. infantum PABP protein (Mw = 65 kDa) was cloned in the pQe30 expression vector and the
recombinant HIS-LiPABP (rLiPABP) was purified by affinity chromatography on Ni-NTA
resin columns (QIAGEN) as described [34]. Briefly, the cells expressing rLiPABP were
Aptamers Targeting L. infantum PABP
PLOSONE | DOI:10.1371/journal.pone.0140048 October 12, 2015 3 / 17
harvested and resuspended in binding buffer (20 mM Tris HCl pH 7.8, 0.5 M NaCl, 8 M urea)
supplemented with 5 mM Imidazol, at 2–5 volumes x g-1 of wet weight. After binding to a Ni-
nitroacetic acid column recombinant proteins were gradually refolded on the affinity column
as described [35]. Afterwards, rLiPABP was eluted with 0.3 M imidazole and stored at -80°C.
Other HIS-tagged Leishmania proteins used in this study were purified in a similar way
(unpublished data). Eukaryotic eIF2 protein was purified from calf cerebral cortex as previ-
ously described [36].
In vitro selection
Selection of DNA aptamers for recombinant L. infantum PABP (rLiPABP) was performed as
described previously [20]. In brief, ssDNA oligonucleotides containing a central randomized
region of 40 nucleotides flanked by two conserved 18-nucleotides regions in each end (RND40,
5’-GCGGATGAAGACTGGTCT-40N-GTTGCTCGTATTTAGGGC-3’) (IBA GmbH, Ger-
many) were denatured at 90°C for 10 minutes and then cooled on ice for 10 min. For the initial
SELEX round, 50 μg of RND40 (Mw = 25 kDa) were mixed with 2 μg of rLiPABP in 200 μL of
selection buffer (20 mM Tris-HCl pH 7.4, 1 mMMgCl2, 150 mM NaCl, 5 mM KCl, 0.2% BSA)
and incubated 26°C for 30 minutes. The bound aptamer-rLiPABP complexes were purified by
adding 20 μL of Ni-NTA superflow (Qiagen) for 1 h at 4°C. After washing three times with
1 mL of selection buffer, the ssDNA-protein complexes were resuspended in 20 μL of distilled
H2O and amplified by 15 cycles of PCR using the primers named F3 (5´ GCGGATGAAGACT
GGTGT 3´) and R3 (5´ GTTGCTCGTATTTAGGGC 3´) under the conditions of 1 μM/primer,
250 μM dNTPs, 2 mMMgCl2 and 1.25 U Taq polymerase in a final volume of 50 μL. PCR prod-
uct was ethanol-precipitated. After 4 rounds, the pool named SEL4LiPABP was amplified and
labeled by PCR using digoxigenin-labeled primer F3 and non-labeled primer R3 for further anal-
ysis. Both non-labeled and labeled primers were obtained from IBA GmbH (Germany).
Aptamer cloning and sequencing and secondary ssDNA structure
prediction
Aptamers were amplified by using 1U/50 μL Taq DNA polymerase (Biotools) in a reaction also
containing 1x PCR buffer, 1.25mMMgCl2, 125 μM dNTPs, 1 μM primer 1 and 1 μM primer 2.
The dsDNA product with ‘A’-overhangs was cloned into pGEM-T Easy-cloning vector (Pro-
mega) following manufacturer’s instructions. Individual clones were sequenced by Sanger
method using T7 (5´-TAATACGACTCACTATAGGG-3´) and Sp6 primers (5´- ATTTAGGT
GACACTATAGAA-3´) (IBA GmbH, Germany).
Selected ssDNA molecules were subjected to secondary structure prediction using the pro-
gram Rapidshare [37], to fold DNA sequences into their minimum free energy (MFE) second-
ary structure, as well as to compare the obtained structures.
Enzyme-Linked OligoNucleotide Assay (ELONA)
ELONA was used to analyze the affinity of the aptamers for the target as in Ramos et al., 2007
[20]. First, in order to assess the enrichment of the selected population, rLiPABP was diluted to
2.5 μg/mL concentration in selection buffer and 200 μL of the solution were incubated in a
96-well microtiter plate (NUNC) overnight at 4°C and, then, washed four times in selection
buffer. Afterwards, digoxigenin-labeled SELLiPABP aptamer population or digoxigenin-
labeled RND40 library were diluted in selection buffer at different concentrations (0–80 nM),
denatured for 10 min at 95°C and then cooled for 10 min on ice. Next, 200 μL of the solution
were added to each well, the plate incubated at 1 h at 26°C and then washed four times with
selection buffer to remove unbound ssDNA. Afterwards, 200 μL of a 1:1000 dilution of anti-
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digoxigenin antibody conjugated with horse-radish peroxidase (POD) (Roche) was added to
the individual wells. Following 1 h incubation at room temperature on a shaking platform, the
plates were washed four times and developed using ABTS solution (Boehringer–Mannheim)
according to the manufacturer’s instruction. OD values at 405 nm were determined using a
microplate reader from TECAN.
In order to determinate the affinity constant of the selected populations or the individual
aptamers to rLiPABP, the protein was plated as above and afterwards, incubated with the
digoxigenin-labeled SELLiPABP aptamer population or the individual aptamers at concentra-
tion indicated in the figure legends, denatured for 10 min at 95°C and cooled for 10 min on ice,
and then incubated at 26°C for 1 h. Next, 200 μL of a 1:1000 dilution of anti-digoxigenin anti-
body conjugated with POD were added to the individual wells and developed as above.
In other set of experiments, rLiPABP was plated to the required concentrations (0–5 μg/
well) and incubated with 200 μL of digoxigenin-labeled SELLiPABP diluted in selection buffer
at 80 nM concentration and the ELONA developed as above. To assess the specificity of the
aptamers, similar experiments were performed coating the wells with 2 μg of LiPABP, other
recombinant Leishmania proteins (LiIF2α, LiIF2β, LiIF2γ, LiH2A, LiP2a) or eukaryotic eIF2
protein, which were incubated with 200 μL of digoxigenin-labeled SELLiPABP aptamer popu-
lations at 40 nM as above.
To study the sensitivity of the aptamers to recognize LiPABP from L. infantum promasti-
gotes, lysates corresponding to increasing number of parasites (0–5000) were plated in coating
solution (KPL) and incubated with digoxigen-labeled aptamers at 10 nM, and the ELONA was
developed as above.
Slot blot analysis with aptamers
Several amounts of rLiPABP (0–25 ng) and 25 ng of BSA, as negative control, were transferred
onto nitrocellulose membranes under vacuum. Filter were washed three times in PBS-T (10
mM sodium phosphate, 0.15 M NaCl, 0.05% Tween-20, pH 7.5) for 10 min and then blocked
with 5% milk in PBS-T for 1 h at room temperature. Afterwards, membranes were incubated
with different concentrations (50–400 nM) of digoxigenin-labeled SELLiPABP aptamer popu-
lation or 50 nM of individual aptamers in selection buffer for 1 h at room temperature. Next,
membranes were washed with selection buffer three times and probed with anti-digoxigenin-
POD antibody diluted 1:1000, for 1 h at room temperature. Excess enzyme was removed by
three subsequent washes with selection buffer. Finally, the membranes were developed with
enhanced chemiluminescence’s kits (GE Healthcare) and exposed to hyperfilm.
Poly (A)-sepharose binding assay
To test the ability of individual aptamers to specifically block LiPABP-poly (A) binding, poly
(A) binding experiments using poly (A)-sepharose microparticles were carried out as described
previously [9]. Briefly, lysates from L. infantum promastigotes (100 μg) or 25 μg of lysates from
HEK293T cells overexpressing Myc-LiPABP, in 200 μL of binding buffer (20 mM Tris-HCl,
pH 7.4, 1 mM DTT, 1 mMMgCl2, 5 mM EDTA and 1 mM PMSF), were incubated with 50 μL
of poly(A)-Sepharose (50%) for 1 h at 4°C in the absence or the presence of 400 pmoles of the
selected aptamers or the naïve RND40 population. The beads were washed six times with bind-
ing buffer and proteins were eluted with Loading/Sample buffer. The membrane was soaked
with blocking buffer (5% non-fat dry milk, 10 mM Tris-HCl at pH 7.5, 100 mMNaCl, 0.1%
Tween-20) 1 hour at room temperature, and incubated with anti-Myc antibody (Santa Cruz
Biotechnology) (to detect recombinant LiPABP expressed in HEK293T cells) or polyclonal
sera from infected dogs (to detect endogenous LiPABP) overnight at 4°C. After repeated
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washing, the membrane was incubated with anti-mouse IgG sheep secondary antibody HRP
conjugate (GE Healthcare) or anti-dog sheep secondary antibody HRP (Bethyl Laboratories,
USA), respectively.
PABP pull-down assay
To test the ability of individual aptamers to specifically bind to and purify the LiPABP presents
in lysates, purification experiments using streptavidin agarose (Solulink) were carried out.
Streptavidin agarose were equilibrated for 30 min at 4°C in buffer A (20 mM Tris-HCl pH 7.6,
1 mM DTT, 1 mM EDTA, 1 mM PMSF, 1 mM benzamidine, 2 mM sodium molybdate, 2 mM
sodium β-glycerophosphate, 0.2 mM sodium orthovanadate, 120 mM KCl, 10 μg/mL anti-
paine, 1 μg/mL leupeptin, 1 μg/mL pepstatin) and 1 mg/ml of cytochrome C to block nonspe-
cific binding. Meanwhile, 50 μg lysates from HEK293T cells overexpressing Flag-LiPABP were
incubated with (125 pmol) of biotin-labeled aptamers for 30 min at 4°C. To carry out the puri-
fication, 30 μL of 50% streptavidin agarose were added to the mixture and incubated for 2 h at
4°C in agitation. Next, samples were centrifuged for 5 min at 3500 g at 4°C and the precipitates
were washed five times with 0.5 mL of buffer A at 4°C. The retained proteins were eluted in 3x
loading buffer and resolved by 10% SDS-PAGE and transferred to polyvinylidene difluoride
(PVDF) membranes. The membrane was soaked with blocking buffer for 1 h at room tempera-
ture, and incubated with anti-Flag antibody (Sigma) overnight at 4°C. After repeated washing,
the membrane was incubated with anti-mouse IgG sheep secondary antibody HRP conjugate
(GE Healthcare).
Statistical analysis
Data are presented as an average value ± standard error of the mean (SEM) from three to six
independent measurements in separate experiments and analyzed using GraphPad Prism v4
(San Diego, CA, USA). The statistical significance was performed by analysis of variance
ANOVA followed by Tukey´s or Dunnett´s test.
Results
Selection and characterization of aptamers against the LiPABP
The aptamer selection target used in this study was recombinant 6xHIS-LiPABP. This protein
has been described and characterized in our lab showing its capability to complex with a poly
(A) oligonucleotide [9]. LiPABP was purified and used as target for four rounds of in vitro
ssDNA aptamer selection with an RND40 degenerate library as described in the Materials and
Methods section. PCR reactions were restricted to 15 cycles to avoid artifacts produced when
high amounts of template are used. We analyze the four rounds of selection by PCR. The
results showed increasing amounts of DNA product in rounds 3 and 4, which is consistent
with a higher recovery of aptamers targeting LiPABP throughout the SELEX process
The initial RND40 population and the selected SELLiPABP pool were then tested for its
ability to bind rLiPABP using ELONA. In only four rounds of aptamer selection, SELLiPABP
population displayed increased binding to rLiPABP protein compared with the initial pool sug-
gesting that it is enriched in ssDNA sequences that recognize rLiPABP relative to the naïve
RND40 population (Fig 1). Consequently, we decided to analyze the binding affinity of the
SELLiPABP aptamer population to L. infantum LiPABP using ELONA and slot blot assays.
Thus, in a first approach, the wells were coated with recombinant LiPABP protein and different
concentrations of digoxigenin-labeled SELLiPABP were tested as described in Materials and
methods section (Fig 2A). Data were analyzed using non-linear regression showing that they
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responds to a one-site binding curve with an equation y = (x × Bmax)/(x + Kd) where Bmax is
the maximal binding and Kd is the concentration of ligand required to reach half-maximal
binding. Results indicate that SELLiPABP is able to detect rLiPABP in a concentration-depen-
dent manner with Kd = 3.87 ± 0.67 nM. In addition, an exhaustive analysis of the data repre-
sented in Fig 2A showed that a concentration so low as 2.48 nM of SELLiPABP is able to detect
from 500 ng (7.5 pmol) of recombinant LiPABP in a significant manner (p<0.01).
In order to determine the sensitivity of the selected SELLiPABP population we performed
an analysis in which wells were coated with quantities ranging from 0–5 μg of recombinant
LiPABP and incubated in the presence of digoxigenin-labeled SELLiPABP as described in
Materials and Methods section. As seen in Fig 2B, it was further confirmed that the interaction
affinity among the protein and the aptamer population is directly proportional to the quantity
of LiPABP. A more detailed analysis of the data indicated that SELLiPABP (80 nM) were able
to significantly detect from 0.625 μg (9.5 pmol) of LiPABP (p<0.01). All the above results con-
firm that SELLiPABP is a suitably enriched population that could be used as a source for isola-
tion of high affinity aptamers.
In the slot blot assays several amounts of recombinant LiPABP and BSA were transferred
onto nitrocellulose membranes and the immobilized proteins were probed with four different
concentrations of digoxigenin-labeled SELLiPABP as described in Materials and methods sec-
tion. As shown in Fig 2C, SELLiPABP showed strong affinity to recombinant LiPABP but did
not show any affinity to negative control BSA, thereby indicating their specificity towards the
LiPABP antigen. In this type of experiments, as few as 6.25 ng of LiPABP were detected after
incubation of the nitrocellulose membrane with 50 nM SELLiPABP.
To study the specificity of SELLiPABP we tested the binding of these aptamers against other
proteins of L. infantum (histone LiH2A, the ribosomal protein LiP2a and potential translation
initiation factors LiIF2α, LiIF2β and LiIF2γ) and the eukaryotic translation initiation factor
(eIF) 2 by ELONA (Fig 2D). Data showed that in the assayed conditions SELLiPABP popula-
tion specifically recognizes LiPABP. Thus, the signal output for LiPABP was significantly
higher than for LiH2A (P<0.001; ANOVA followed by Tukey´s test) meanwhile the signal for
the other proteins was similar to that for negative control. The recognition of LiH2A might be
Fig 1. Aptamers are selected after 4 round of SELEX. The stringency of the SELEX procedure was
monitored using ELONA as described in “Materials and Methods” section. SELEX pool from round 4
(SELLiPABP) and the starting round (RND40) were assayed for binding to LiPABP protein. Recombinant
LiPABP was plated at 500 ng/well (7.5 pmol/well) and incubated with 200 μL of digoxigenin labeled
SELLiPABP aptamer population or digoxigenin-labeled RND40 library (0–80 nM). Finally, anti-digoxigenin-
POD antibodies were added plate was revealed with ABTS solution at 405 nm. All the experiments were
made in triplicate and average of two different experiments is shown.
doi:10.1371/journal.pone.0140048.g001
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probably due to the basic nature of the histone and also the high amount of protein used in the
assay. Additionally, western blot assays were also performed in which cytoplasmic and nuclear
fractions from promastigotes of L. infantum and recombinant LiPABP protein were blotted on
PVDF membranes and then probed with digoxigenin-labeled SELLiPABP. However, aptamer
population was not able to detect specifically LiPABP in these assays in which the protein is
Fig 2. Binding capability and specificity of the SELLiPABP aptamer population for LiPABP. ELONA (A, B andD) and slot-blot (C) assays were
performed as described in “Materials and methods” section. (A) Recombinant LiPABP was plated at 500 ng/well (7.5 pmol/well) and incubated with the
digoxigenin-labeled SELLiPABP aptamer population at the concentrations indicated (0–80 nM). All the experiments were made in triplicate and average of
four different experiments is shown. (B) Recombinant LiPABP was plated to several concentrations between 0–5 μg/well (0–75 pmol/well) and incubated
with 80 nM of digoxigenin-labeled SELLiPABP aptamer population. All the experiments were made in triplicate and average of four different experiments is
shown. Statistical significance between each concentration of LiPABP protein and the value obtained for the blank **, p<0.01. (C) BSA and rLIPABP at the
concentration indicated were fixed under vacuum to a nitrocellulose membrane. Membranes were blotted with digoxigenin-labeled SELLiPABP aptamer
population at several concentrations. Afterwards, the membrane was probed with anti-digoxigenin-POD antibodies, developed with enhanced
chemiluminescence’s kits and exposed to hyperfilm. The experiment shown is representative of at least three different experiments. (D) Recombinant
proteins LiPABP, LiIF2α, LiIF2β, LiIF2γ, LiH2A, LiP2a or eukaryotic eIF2 protein were plated at 2 μg/well and incubated with 40 nM of digoxigenin-labeled
SELLiPABP aptamer population. Afterwards, anti-digoxigenin-POD antibody was added and the plates were developed using ABTS solution. All the
experiments were made in triplicate and average of four different experiments is shown (a, p<0.001 versus LiPABP value; ***, p<0.001 versus value
obtained for the blank).
doi:10.1371/journal.pone.0140048.g002
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previously denatured (data not shown). It is not surprising because aptamers are selected using
the native PABP and, consequently, they can recognize or not the denatured protein.
Isolation and molecular characterization of high-affinity individual
aptamer sequences
In view of these results, we decided to isolate and identify aptamer sequences that bind LiPABP
with high affinity from the SELLiPABP population obtained after four rounds of selection to
determinate whether or not these aptamers could be used as biorecognition molecules and lab-
oratory tools.
With this purpose aptamer population was cloned and sequenced, and the affinities of the
individual anti-LiPABP aptamers for their target were estimated by ELONA as above. Results
showed that most of the aptamers analyzed bind to LiPABP with higher affinities than RND40
control and SELLiPABP population (Fig 3A) and, moreover, that three of them, ApPABP#3,
ApPABP#7 and ApPABP#11, bound to the target with affinities significantly higher than the
others. No binding to an unspecific protein (BSA) occurred under these conditions (data not
shown).
In order to calculate the dissociation constant of the selected aptamers, ELONA assays were
carried out as above. As shown in Fig 3B, ApPABP#3, ApPABP#7 and ApPABP#11 displayed
increased binding to rLiPABP in a concentration-dependent manner. Analysis of the data
using non-linear regression indicated that aptamers detect rLiPABP in a concentration-depen-
dent manner with Kd = 5.4 ± 1.1 nM for aptamer ApPABP#3, Kd = 6.0 ± 2.6 nM for aptamer
ApPABP#7 and Kd = 10.8 ± 2.7 nM for aptamer ApPABP#11.
Next, slot blot assays were performed as above and the results are shown in Fig 3C. As it can
be observed, aptamers ApPABP#3, ApPABP#7 and ApPABP#11 showed strong affinity to rLi-
PABP but not to negative control BSA, thereby indicating their specificity towards the LiPABP
target. Interestingly, the results show that only 50 nM of each of the three aptamers are able to
detect as few as 6.25 ng of LiPABP.
In order to determinate the lowest number of L. infantum promastigotes present in a sample
detected by ApPABP aptamers, we performed ELONA assays in which total lysates corre-
sponding to increasing amounts of parasites (0–5000) were plated and incubated in the pres-
ence of ApPABP#3, ApPABP#7 and ApPABP#11. The results showed that the three aptamers
were able to detect LiPABP from 2500 promastigotes in a significant manner (Fig 3D).
Structural characterization of the aptamers
To proceed to their structural characterization, the sequences of ApPABP#3, ApPABP#7 and
ApPABP#11 were analyzed using the program Rapidshape (http://bibiserv.techfak.uni-
bielefeld.de/rapidshapes/) [37] and the potential most stable secondary structures for each
aptamer in the same condition that those used during selection are shown in Fig 4. Secondary
structure prediction indicates that, taking into account the free energy value, ApPABP#7
would be the more stable aptamer (ΔG = -14.00 kcal/mol), followed by ApPABP#11 (ΔG =
-9.30 kcal/mol) and ApPABP#3 (ΔG = -7.40 kcal/mol.). It is interesting to point out that the
three aptamers showed non conserved sequences and different secondary structures, suggest-
ing that each of them could bind LiPABP with different affinity and, moreover, they could rec-
ognize different “aptatopes” on the protein surface.
Aptamers inhibit LiPABP-poly (A) complex formation
The potential effect of aptamers on the interaction of LiPABP with the poly (A) molecule was
investigated by a competition assay using the selected aptamers or the naïve RND40
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population. As shown in Fig 5A, the amount of LiPABP bound to poly(A)-sepharose was
reduced in the presence of ApPABP#11 (30%), while unaffected in the presence of aptamers
ApPABP#3 and ApPABP#7 and RND40. To reinforce this result we have also performed the
same experiments with lysates from HEK293T cells expressing myc-LiPABP and the band cor-
responding to the protein bound to poly (A)-sepharose decreased 80% in the presence of
ApPABP#11 meanwhile aptamers ApPABP#3 and ApPABP#7 only produce a slight effect.
These results indicate that only aptamer ApPABP#11 is able to inhibit LiPABP:poly (A) bind-
ing suggesting that this aptamer may recognize the protein at the poly (A) binding site.
Fig 3. Aptamers ApPABP#3, ApPABP#7 and ApPABP#11 show a high affinity for LiPABP. (A) Analysis of the binding capability of the individual
aptamers by ELONA. rLiPABP was plated at 1 μg/well (15 pmol/well) and incubated with the digoxigenin-labeled SELLiPABP aptamer population at 80 nM
and, finally, incubated with anti-digoxigenin-POD antibodies and revealed with ABTS solution at 405 nm (a, p<0.001; c, p<0.05 versus RND40 value; ***,
p<0.001 versus SELLiPABP value). (B) Binding affinity of ApPABP#3, ApPABP#7 and ApPABP11 to LiPABP by ELONA. Recombinant protein LiPABP was
plated at 500 ng/well (7.5 pmol/well), incubated with the digoxigenin-labeled aptamers at the concentrations between 0 and 200 nM and revealed as above.
All the experiments were made in triplicate and average of four different experiments is shown. (C) BSA and rLiPABP at the concentration indicated in the
figure were fixed under vacuum to a nitrocellulose membrane. Membranes were blotted with digoxigenin-labeled ApPABP#3, ApPABP#7 and ApPABP#11
aptamers at 50 nM concentration. Afterwards, the membranes were probed with anti-digoxigenin-POD antibodies, developed with enhanced
chemiluminescence’s kits and exposed to hyperfilm. The experiments shown are representative of at least three different experiments. (D) Sensitivity of the
aptamers to recognize LiPABP from L. infantum promastigotes was analyzed by ELONA. Total lysates corresponding to increasing amounts of parasites
(102-5x103) were plated and incubated in the presence of digoxigenin-labeled ApPABP#3, ApPABP#7 and ApPABP#11 at 10 nM and assays were
performed as in Fig 1. All the experiments were made in triplicate and average of 3–4 different experiments is shown. Statistical significance was calculated
between each parasite number and the value obtained for 0 parasites (b, p<0.01; c, p<0.05).
doi:10.1371/journal.pone.0140048.g003
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Aptaprecipitation of LiPABP from cell lysates
In order to study whether or not some of the selected aptamers are capable to pull down the
recombinant LiPABP, biotinylated aptamers or biotinylated 38x(AG) unstructured ssDNA
were mixed with LiPABP-expressing HEK293 cell lysates and the complexes pulled down with
streptavidin beads. As it can be observed in Fig 5B, a band corresponding to LiPABP in the
three aptamer-bound fractions demonstrated the high affinity of these aptamers for LiPABP.
Interestingly, aptamers ApPABP#3 and ApPABP#7 were able to purify LiPABP from lysates
with a higher efficiency (above 75%) than ApPABP#11 (below 50%).
Discussion
Trypanosomatid parasites produce a great deal of chronic diseases affecting hundreds of mil-
lions people mainly in underdeveloped countries. Among these parasites, Leishmania produces
a devastating human disease, leishmaniasis, which severely affects millions of people in Asia,
Africa and South America. Although diagnosis and treatment of diseases caused by parasites
has undergone major changes due to increased knowledge and technological advances that
now allow for more rapid and accurate diagnosis of parasitic diseases, they still need severe
improvements. In fact, few major advances in clinical diagnostic testing have been made since
introduction of PCR, although new technologies have been investigated [38]. The use of apta-
mers for clinical diagnosis and therapy is attractive due to their small size, stable folding
Fig 4. Predicted structural folding of selected ssDNA aptamers for LiPABP. The DNA sequences of ApPABP#3, ApPABP#7 and ApPABP#11
aptamers were analyzed using the program Rapidshare. The resultant predicted secondary structures of the three selected aptamers are shown. The
nucleotides labeled in red are those conserved in the sequence of the three aptamers.
doi:10.1371/journal.pone.0140048.g004
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structure, and economy. There has been rapid advancement in application of such aptamers in
disease diagnosis, imaging, and new biomarker discovery [39].
During the last years, we have selected aptamers that specifically recognize Leishmania pro-
teins in order to develop detection/therapeutic systems for leishmaniasis. In this paper, we
describe the selection and characterization of DNA aptamers that bind LiPABP with high affin-
ity and specificity. In only four rounds of selection, the aptamer pool selected against the
LiPABP (SELLiPABP) bind to the target with very high-affinity relative to the naïve RND40
population (Fig 1). From SELLiPABP we have identified three aptamers (ApPABP#3,
ApPABP#7 and ApPABP#11) able to bind LiPABP with very high affinity, in the range of the
best aptamers previously described [40].
Fig 5. Aptamers inhibit LiPABP-poly (A) complex formation and are capable to pull down LiPABP. (A)
Representative blots showing the endogenous LiPABP (top) or Myc-LiPABP expressed in HEK293T cells
(bottom) bound to poly (A)-sepharose in the presence or not of the different ApPABP aptamers or RND40 are
shown. Input corresponding to 50 μg of L. infantum lysate or 10 μg of lysate from cells expressing Myc-
LiPABP was loaded in parallel. Bands were quantified as described in Material and Methods section and the
values normalized relative to the LiPABP bound in the absence aptamers. Blot shown is representative of
three different experiments. (B) Biotin-labeled ApPABP#3, ApPABP#7 and ApPABP#11 or biotinylated 38x
(AG) unstructured ssDNA were mixed with 50 μg of Flag-LiPABP-expressing HEK293T cell lysates and the
complexes pulled down with streptavidin beads, and Flag-LIPABP protein was detect by immunoblot. A
representative blot is shown at the top. Input corresponding to 15 μg of lysate from cells expressing Flag-
LiPABP loaded in parallel. Bands were quantified as described in Material and methods section and the
values normalized relative to the total Flag-LiPABP in the lysate. Bars represent the mean ± S.E.M. of two
different experiments.
doi:10.1371/journal.pone.0140048.g005
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In 2007, Bruno et al [41] reported the development of several DNA aptamers against surface
molecules from Leishmania donovani promastigotes to be used with diagnostic purposes. Sev-
eral of these aptamers exhibited very high affinity against L. donovani and, at lesser extent, L.
tropica showing quantitative binding data in ELONA assays. Most recently, Operational Tech-
nologies Corporation (OpTech) has completed a successful Phase I SBIR contract in which 72
new candidates DNA aptamer sequences against Leishmania major were developed and
screened by ELISA-like plate assay (http://www.sbir.gov/sbirsearch/detail/383773). Taking into
account our interest in the development of diagnostic tools for leishmaniasis, we have selected
and characterized aptamers against Leishmania infantum KMP-11 [18], and histones LiH2A
[20, 21] and LiH3 [22] showing affinities and specificities similar than those obtained for L.
donovani. In this paper we demonstrated that high affinity aptamers against LiPABP are able
to detect the amount of protein corresponding to only 2500 parasites in a significant manner
using ELONA platform. Although this detection limit is far from that desired for a diagnostic
system, in our laboratory are working on the development of a more sensible method also
based on ELONA, which may be potentially used as a novel diagnostic tool. It is also interesting
to note that as far as we know, there are no differences in LiPABP in the promastigote and
amastigote stage. In fact, this is an interesting diagnostic advantage due to the possibility of
detecting parasite protein released in either forms of Leishmania. Some years ago, we reported
the development of an electrochemical biosensor based on aptamers that can recognize and
specifically detect the presence of Leishmania infantum KMP-11 [19]. In that paper, the target
protein was conjugated with gold nanoparticles and the complexes electrodeposited on gold
screen printed electrodes. Then, complexes were incubated in the presence of digoxigenin-
labeled aptamers that specifically recognize LiKMP-11. Using this method with the new apta-
mers against L. infantum proteins would be a possibility for the development of a diagnostic
test. Additionally, the use of a pool of aptamers recognizing several proteins of the parasites
could be a successful diagnostic strategy in different platforms.
From a therapeutic point of view, several strategies have been addressed to affect a parasite
organism with aptamers. The first one tries to block the interaction between the parasite and
the host. At this respect, aptamers against P. falciparum erythrocyte membrane protein 1
(PfEMP1) [42] and others selected against host-cell matrix receptors (heparin sulphate, fibro-
nectin, laminin and thrombospondin) [43] have been obtained. A second strategy consists in
attack the parasite intracellularly and, with this purpose, aptamers targeting heme group which
inhibit P. falciparum growth [44] and others interfering in the intracellular RNA transport in
L. tropica [45] have been selected. In other strategy, aptamers targeting invariant polypeptides
in African trypanosomes, which are internalized via receptor, could be used as a specific drug
delivery system into the parasite [46]. Finally, RNA aptamers that bind to VSGs are able to rec-
ognize different VSG variants and bind to the surface of live trypanosomes to re-direct the
immune response of the infected host back to the surface of the parasite independently of the
expressed VSG variant. Moreover, these aptamers tethered to an antigenic side group are capa-
ble of directing antibodies to the surface of the parasite in vitro providing a new strategy for a
therapeutic intervention to fight sleeping sickness [47]. The use of aptamers as therapeutic
agents against leishmaniasis diseases has also been studied. Bhattacharyya et al [48] demon-
strated that a large number of cytoplasmic tRNAs are imported into the kinetoplast-mitochon-
drion of Leishmania by a receptor-mediated process. In consequence, one important potential
role for aptamers in the parasitic diseases treatments would be to interfere in the intracellular
RNA transport. Using the SELEX procedure with L. tropicamitochondria as target, these
authors was able to obtain four aptamers containing sequence motifs present in the anticodon
arm, the D arm, the V-T region, and acceptor stem of known tRNAs. The aptamers proved to
have nanomolar affinities for mitochondria, in the same range as that of natural sequences.
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These results opened the way to new research lines in mitochondrial mediated tRNAs trans-
port, not only in parasites but also in yeasts and mammals [49]. In a similar way, a specific
blocking of the interaction between LiPABP and the poly (A) tail of the mRNA by specific
aptamers affecting protein translation in Leishmania and could be an interesting therapeutic
approach. Our results point out that the three selected aptamers bind LiPABP at different sites
because only ApPABP#11 inhibits the LiPABP-poly (A) interaction, while aptamers
ApPABP#3 and ApPABP#7 do not have any effect. Taking into account this, we can conclude
that aptamer ApPABP#11 could be a potential inhibitor of translation affecting the biology of
the parasite. However, this aptamer would have to reach its target into the parasite, who is
mainly located into the lysosome of the host cell. In our opinion, aptamers targeting parasite
intracellular proteins are not good candidates for leishmaniasis treatment.
It is important to point out that aptamers showing high affinity for the target are not always
capable of work in all potential applications. We described in this work the application of apta-
mer affinity chromatography for one-step purification of LiPABP from a complex mixture.
Our results clearly demonstrate that aptamers ApPABP#3 and ApPABP#7 are able to produce
a more effective purification of LiPABP from lysates of cells overexpressing the recombinant
protein than ApPABP#11, suggesting different binding sites (aptatope) on the protein surface
recognized by the aptamers. The feasibility of the method was demonstrated on L. infantum
PABP overexpressed in HEK293 cells, but we anticipate that it could be used for any other pro-
tein for which aptamer development is possible.
In summary, we have generated a population of ssDNA aptamers that bind with high speci-
ficity to L. infantum PABP antigen and do not bind to other proteins of the parasite. The cur-
rent work demonstrates that aptamers can be used for detection of specific targets in an
ELONA format. It is important to point out that aptamers have a great potential to circumvent
limitations associated with antibodies. Although the antibody detection system is the gold stan-
dard for protein detection and identification, the data presented in this study strongly supports,
due to easier and lower cost of their production, the feasibility of the aptamer-based diagnostic
system. In conclusion, it is reasonable to expect that the ELONA platform using aptamers will
stimulate the development of other detection systems in which antibodies have been previously
used. Aptamer affecting the binding of LiPABP to the poly (A) tail is a potential candidate for
leishmaniasis therapeutic. Furthermore, some of the developed aptamers can be used in the
affinity purification of the target protein from cell lysates. Considering the extreme complexity
of cell lysate, aptaprecipitation can be extended to potentially any biological mixture such as
blood, urine and others. This method facilitates the faster recovering of recombinant proteins
in pure form for their structural and functional studies as well as for other biomedical
applications.
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